Epithelial ovarian cancer (EOC) frequently relapses with rising chemoresistance. This phase 1/2 trial evaluates MVP-S vaccination plus pembrolizumab and cyclophosphamide in recurrent EOC, assessing safety, clinical efficacy outcomes, and MVP-S-specific immunity.
- Ana C. Veneziani
- Stephanie Lheureux
- Amit M. Oza